Marta Guix

3.7k total citations
43 papers, 2.5k citations indexed

About

Marta Guix is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Marta Guix has authored 43 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 18 papers in Pulmonary and Respiratory Medicine and 13 papers in Molecular Biology. Recurrent topics in Marta Guix's work include Lung Cancer Treatments and Mutations (9 papers), HER2/EGFR in Cancer Research (8 papers) and Renal cell carcinoma treatment (6 papers). Marta Guix is often cited by papers focused on Lung Cancer Treatments and Mutations (9 papers), HER2/EGFR in Cancer Research (8 papers) and Renal cell carcinoma treatment (6 papers). Marta Guix collaborates with scholars based in Spain, United States and Canada. Marta Guix's co-authors include Carlos L. Arteaga, Cammie Rinehart, Teresa C. Dugger, Jeffrey A. Engelman, Marianela Pérez-Torres, Christoph A. Ritter, Joaquim Bellmunt, Shizhen Emily Wang, Maria G. Olivares and Youngchul Song and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Marta Guix

43 papers receiving 2.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Marta Guix Spain	17	1.4k	1.1k	714	599	398	43	2.5k
Vincent Haddad United Kingdom	16	1.5k 1.1×	907 0.8×	1.3k 1.9×	485 0.8×	252 0.6×	36	2.9k
Waldemar Wilczak Germany	30	842 0.6×	1.1k 0.9×	826 1.2×	599 1.0×	234 0.6×	93	2.3k
Ian Lorimer Canada	17	1.6k 1.1×	888 0.8×	1.6k 2.2×	454 0.8×	252 0.6×	28	2.6k
Annarita Destro Italy	29	1.5k 1.0×	1.2k 1.1×	1.6k 2.2×	621 1.0×	304 0.8×	58	3.7k
Frances Daley United Kingdom	27	759 0.5×	886 0.8×	539 0.8×	934 1.6×	528 1.3×	52	2.3k
Akihiko Shimomura Japan	22	1.1k 0.8×	751 0.7×	536 0.8×	537 0.9×	331 0.8×	132	2.0k
Yoichi Naito Japan	27	1.7k 1.2×	623 0.5×	1.1k 1.5×	428 0.7×	348 0.9×	150	2.7k
Emily Chan United States	20	2.1k 1.4×	1.1k 1.0×	762 1.1×	420 0.7×	179 0.4×	46	2.9k
Wing‐Kai Chan Taiwan	22	1.4k 1.0×	1.4k 1.2×	1.2k 1.7×	828 1.4×	151 0.4×	57	3.2k
Florence Lerebours France	29	1.4k 1.0×	915 0.8×	692 1.0×	1.2k 2.0×	322 0.8×	97	2.6k

Countries citing papers authored by Marta Guix

Since Specialization

Citations

This map shows the geographic impact of Marta Guix's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marta Guix with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marta Guix more than expected).

Fields of papers citing papers by Marta Guix

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marta Guix. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marta Guix. The network helps show where Marta Guix may publish in the future.

Co-authorship network of co-authors of Marta Guix

This figure shows the co-authorship network connecting the top 25 collaborators of Marta Guix. A scholar is included among the top collaborators of Marta Guix based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marta Guix. Marta Guix is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

García‐Alfonso, Pilar, Élena Elez, David Páez, et al.. (2024). Maintenance with 5-FU/LV-aflibercept after induction with FOLFIRI-aflibercept versus FOLFIRI-aflibercept until progression as second-line treatment in older adults with metastatic colorectal cancer: the AFEMA phase II randomized trial. ESMO Open. 9(12). 103986–103986. 1 indexed citations

Hitt, Ricardo, L. Iglesias, Antonio López–Pousa, et al.. (2020). Long-term outcomes of induction chemotherapy followed by chemoradiotherapy vs chemoradiotherapy alone as treatment of unresectable head and neck cancer: follow-up of the Spanish Head and Neck Cancer Group (TTCC) 2503 Trial. Clinical & Translational Oncology. 23(4). 764–772. 11 indexed citations

Bellmunt, Joaquim, Emilio Esteban, Juan Manuel Sepúlveda-Sánchez, et al.. (2019). Pazopanib as Second-line Antiangiogenic Treatment in Metastatic Renal Cell Carcinoma After Tyrosine Kinase Inhibitor (TKI) Failure: A Phase 2 Trial Exploring Immune-related Biomarkers for Testing in the Post-immunotherapy/TKI Era. European Urology Oncology. 4(3). 502–505. 5 indexed citations

Taberna, Miren, M. Mena, Sara Tous, et al.. (2018). HPV-relatedness definitions for classifying HPV-related oropharyngeal cancer patient do impact on TNM classification and patients’ survival. PLoS ONE. 13(4). e0194107–e0194107. 12 indexed citations

Taberna, Miren, Montserrat Torres, María Alejo, et al.. (2018). The Use of HPV16-E5, EGFR, and pEGFR as Prognostic Biomarkers for Oropharyngeal Cancer Patients. Frontiers in Oncology. 8. 589–589. 21 indexed citations

Méndez-Vidal, María José, Urbano Anido, Isabel Chirivella, et al.. (2018). Pazopanib: Evidence review and clinical practice in the management of advanced renal cell carcinoma. BMC Pharmacology and Toxicology. 19(1). 77–77. 20 indexed citations

Suárez, Cristina, Marc Campayo, R. Bastús, et al.. (2018). Prognostic and Predictive Factors for Renal Cell Carcinoma. Targeted Oncology. 13(3). 309–331. 7 indexed citations

Vidal, Joana, Alba Dalmases, Frederick S. Jones, et al.. (2017). Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients. Annals of Oncology. 28(6). 1325–1332. 255 indexed citations

Morales‐Barrera, Rafael, Joaquim Bellmunt, Cristina Suárez, et al.. (2012). Cisplatin and gemcitabine administered every two weeks in patients with locally advanced or metastatic urothelial carcinoma and impaired renal function. European Journal of Cancer. 48(12). 1816–1821. 38 indexed citations

10.

Bellmunt, Joaquim, Anna Orsola, Thomas Wiegel, et al.. (2011). Bladder cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 22(3). vi45–vi49. 197 indexed citations

11.

Miller, Todd W., Marianela Pérez-Torres, Archana Narasanna, et al.. (2009). Loss of Phosphatase and Tensin Homologue Deleted on Chromosome 10 Engages ErbB3 and Insulin-Like Growth Factor-I Receptor Signaling to Promote Antiestrogen Resistance in Breast Cancer. Cancer Research. 69(10). 4192–4201. 141 indexed citations

12.

Bellmunt, Joaquim & Marta Guix. (2009). The medical management of metastatic renal cell carcinoma: integrating new guidelines and recommendations. British Journal of Urology. 103(5). 572–577. 34 indexed citations

13.

Guix, Marta, Anthony C. Faber, Shizhen Emily Wang, et al.. (2008). Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. Journal of Clinical Investigation. 118(7). 2609–19. 455 indexed citations

14.

Font, Albert, Ramón Salazar, Joan Maurel, et al.. (2008). Cisplatin plus weekly CPT-11/docetaxel in advanced esophagogastric cancer: a phase I study with pharmacogenetic assessment of XPD, XRCC3 and UGT1A1 polymorphisms. Cancer Chemotherapy and Pharmacology. 62(6). 1075–1083. 16 indexed citations

15.

Guix, Marta, Ingrid A. Mayer, Ingrid M. Meszoely, & Carlos L. Arteaga. (2008). Evaluation of biological agents targeted at early-stage disease. Breast Cancer Research. 10(S4). S25–S25. 3 indexed citations

16.

Yang, Li, Joseph M. Amann, Takefumi Kikuchi, et al.. (2007). Inhibition of Epidermal Growth Factor Receptor Signaling Elevates 15-Hydroxyprostaglandin Dehydrogenase in Non–Small-Cell Lung Cancer. Cancer Research. 67(12). 5587–5593. 50 indexed citations

17.

Biswas, Swati, Marta Guix, Cammie Rinehart, et al.. (2007). Inhibition of TGF-β with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression. Journal of Clinical Investigation. 117(5). 1305–1313. 290 indexed citations

18.

Ritter, Christoph A., Marianela Pérez-Torres, Cammie Rinehart, et al.. (2007). Human Breast Cancer Cells Selected for Resistance to Trastuzumab In vivo Overexpress Epidermal Growth Factor Receptor and ErbB Ligands and Remain Dependent on the ErbB Receptor Network. Clinical Cancer Research. 13(16). 4909–4919. 388 indexed citations

19.

Pérez-Torres, Marianela, Marta Guix, Adriana González, & Carlos L. Arteaga. (2006). Epidermal Growth Factor Receptor (EGFR) Antibody Down-regulates Mutant Receptors and Inhibits Tumors Expressing EGFR Mutations. Journal of Biological Chemistry. 281(52). 40183–40192. 80 indexed citations

20.

Reyzer, Michelle L., Robert L. Caldwell, Teresa C. Dugger, et al.. (2004). Early Changes in Protein Expression Detected by Mass Spectrometry Predict Tumor Response to Molecular Therapeutics. Cancer Research. 64(24). 9093–9100. 110 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact